Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Myotome adaptability confers developmental robustness to somitic myogenesis in response to fibre number alteration.

Roy SD, Williams VC, Pipalia TG, Li K, Hammond CL, Knappe S, Knight RD, Hughes SM.

Dev Biol. 2017 Nov 15;431(2):321-335. doi: 10.1016/j.ydbio.2017.08.029. Epub 2017 Sep 5.

2.

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M.

J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25.

3.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS.

Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.

4.

Functional in vivo imaging using fluorescence lifetime light-sheet microscopy.

Mitchell CA, Poland SP, Seyforth J, Nedbal J, Gelot T, Huq T, Holst G, Knight RD, Ameer-Beg SM.

Opt Lett. 2017 Apr 1;42(7):1269-1272. doi: 10.1364/OL.42.001269.

PMID:
28362747
5.

Cochlear implants in the management of hearing loss in Neurofibromatosis Type 2.

Harris F, Tysome JR, Donnelly N, Durie-Gair J, Crundwell G, Tam YC, Knight RD, Vanat ZH, Folland N, Axon P.

Cochlear Implants Int. 2017 May;18(3):171-179. doi: 10.1080/14670100.2017.1300723. Epub 2017 Mar 24.

PMID:
28335700
6.

Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy.

Moyle LA, Blanc E, Jaka O, Prueller J, Banerji CR, Tedesco FS, Harridge SD, Knight RD, Zammit PS.

Elife. 2016 Nov 14;5. pii: e11405. doi: 10.7554/eLife.11405.

7.

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A.

Leukemia. 2015 Dec;29(12):2452. doi: 10.1038/leu.2015.312. No abstract available.

PMID:
26648407
8.

A population of Pax7-expressing muscle progenitor cells show differential responses to muscle injury dependent on developmental stage and injury extent.

Knappe S, Zammit PS, Knight RD.

Front Aging Neurosci. 2015 Aug 25;7:161. doi: 10.3389/fnagi.2015.00161. eCollection 2015.

9.

Dissecting the role of Wnt signaling and its interactions with FGF signaling during midbrain neurogenesis.

Dyer C, Blanc E, Stanley RJ, Knight RD.

Neurogenesis (Austin). 2015 Sep 21;2(1):e1057313. doi: 10.1080/23262133.2015.1057313. eCollection 2015.

10.

Development of a doubly weighted Gerchberg-Saxton algorithm for use in multibeam imaging applications.

Poland SP, Krstajić N, Knight RD, Henderson RK, Ameer-Beg SM.

Opt Lett. 2014 Apr 15;39(8):2431-4. doi: 10.1364/OL.39.002431.

PMID:
24979011
11.

Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in humans.

Zeldis JB, Carter TL, Knight RD, Hui J.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):E4819. doi: 10.1073/pnas.1317084110. Epub 2013 Dec 3. No abstract available.

12.

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A; MDS-003 Study Investigators.

Leukemia. 2014 May;28(5):1033-40. doi: 10.1038/leu.2013.305. Epub 2013 Oct 22. Erratum in: Leukemia. 2015 Dec;29(12):2452.

13.

English consensus protocol evaluating candidacy for auditory brainstem and cochlear implantation in neurofibromatosis type 2.

Tysome JR, Axon PR, Donnelly NP, Evans DG, Ferner RE, O'Connor AF, Freeman SR, Gleeson M, Halliday D, Harris F, Jiang D, Kerr R, King A, Knight RD, Lloyd SK, Macfarlane R, Mannion R, Mawman D, O'Driscoll M, Parry A, Ramsden J, Ramsden R, Rutherford SA, Saeed SR, Thomas N, Vanat ZH.

Otol Neurotol. 2013 Dec;34(9):1743-7. doi: 10.1097/MAO.0b013e3182a1a8b4.

PMID:
24136318
14.

Ret signalling integrates a craniofacial muscle module during development.

Knight RD, Mebus K, d'Angelo A, Yokoya K, Heanue T; Tübingen 2000 Screen Consortium, Roehl H.

Development. 2011 May;138(10):2015-24. doi: 10.1242/dev.061002. Epub 2011 Apr 13.

15.

Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.

San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):38-43. doi: 10.3816/CLML.2010.n.120.

PMID:
21273172
16.

Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.

Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A.

Melanoma Res. 2010 Dec;20(6):501-6. doi: 10.1097/CMR.0b013e32833faf18.

PMID:
20859231
17.

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.

Harousseau JL, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Haematologica. 2010 Oct;95(10):1738-44. doi: 10.3324/haematol.2009.015917. Epub 2010 May 11.

18.

Lenalidomide in multiple myeloma: current role and future directions.

Zeldis JB, Knight RD, Jacques C, Tozer A, Bizzari JP.

Expert Opin Pharmacother. 2010 Apr;11(5):829-42. doi: 10.1517/14656561003645611. Review. Erratum in: Expert Opin Pharmacother. 2010 Sep;11(13):2273. Expert Opin Pharmacother. 2011 Mar;12(4):679.

PMID:
20210686
19.

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.

Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J.

Cancer. 2010 Jan 1;116(1):146-54. doi: 10.1002/cncr.24686.

20.

Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.

Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY.

Cancer. 2009 Nov 15;115(22):5228-36. doi: 10.1002/cncr.24576.

21.

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Leukemia. 2009 Nov;23(11):2147-52. doi: 10.1038/leu.2009.147. Epub 2009 Jul 23.

PMID:
19626046
22.

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.

Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, Kumar S, Bahlis NJ, Alsina M, Vescio R, Coutre SE, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V.

Br J Haematol. 2009 Jul;146(2):164-70. doi: 10.1111/j.1365-2141.2009.07728.x. Epub 2009 May 26.

23.

Re: Noise levels generated within the external auditory canal during microsuction aural toilet and the effect on hearing: a prospective controlled series.

Baguley DM, Knight RD.

Clin Otolaryngol. 2009 Jun;34(3):261; author reply 262. doi: 10.1111/j.1749-4486.2009.01935.x. No abstract available.

PMID:
19531188
24.

Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.

Palumbo A, Falco P, Falcone A, Benevolo G, Canepa L, Gay F, Larocca A, Magarotto V, Gozzetti A, Luraschi A, Morabito F, Nozza A, Knight RD, Zeldis JB, Boccadoro M, Petrucci MT.

Clin Lymphoma Myeloma. 2009 Apr;9(2):145-50. doi: 10.3816/CLM.2009.n.035.

PMID:
19406725
25.

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, Facon T, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD, Dimopoulos MA.

Eur J Haematol. 2009 Jun;82(6):426-32. doi: 10.1111/j.1600-0609.2009.01257.x. Epub 2009 Mar 19.

26.

Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.

Yang X, Brandenburg NA, Freeman J, Salomon ML, Zeldis JB, Knight RD, Bwire R.

Clin Drug Investig. 2009;29(3):161-71. doi: 10.2165/00044011-200929030-00003.

PMID:
19243209
27.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.

28.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC.

J Clin Oncol. 2008 May 20;26(15):2519-25. doi: 10.1200/JCO.2007.13.9709. Epub 2008 Apr 21.

29.

Mandibular arch muscle identity is regulated by a conserved molecular process during vertebrate development.

Knight RD, Mebus K, Roehl HH.

J Exp Zool B Mol Dev Evol. 2008 Jun 15;310(4):355-69. doi: 10.1002/jez.b.21215.

PMID:
18338789
30.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators.

N Engl J Med. 2007 Nov 22;357(21):2133-42.

31.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators.

N Engl J Med. 2007 Nov 22;357(21):2123-32. Erratum in: N Engl J Med. 2009 Jul 30;361(5):544.

32.

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.

Moutouh-de Parseval LA, Weiss L, DeLap RJ, Knight RD, Zeldis JB.

J Clin Oncol. 2007 Nov 1;25(31):5047. No abstract available.

PMID:
17971612
33.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF.

Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24.

34.

Tfap2 transcription factors in zebrafish neural crest development and ectodermal evolution.

Hoffman TL, Javier AL, Campeau SA, Knight RD, Schilling TF.

J Exp Zool B Mol Dev Evol. 2007 Sep 15;308(5):679-91.

PMID:
17724731
35.

Evolution of symbiotic bacteria in the distal human intestine.

Xu J, Mahowald MA, Ley RE, Lozupone CA, Hamady M, Martens EC, Henrissat B, Coutinho PM, Minx P, Latreille P, Cordum H, Van Brunt A, Kim K, Fulton RS, Fulton LA, Clifton SW, Wilson RK, Knight RD, Gordon JI.

PLoS Biol. 2007 Jul;5(7):e156. Epub 2007 Jun 19.

37.

Cranial neural crest and development of the head skeleton.

Knight RD, Schilling TF.

Adv Exp Med Biol. 2006;589:120-33. Review.

PMID:
17076278
38.

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.

Sharma RA, Steward WP, Daines CA, Knight RD, O'Byrne KJ, Dalgleish AG.

Eur J Cancer. 2006 Sep;42(14):2318-25. Epub 2006 Aug 8.

PMID:
16899362
39.

Parallel evolution of the genetic code in arthropod mitochondrial genomes.

Abascal F, Posada D, Knight RD, Zardoya R.

PLoS Biol. 2006 May;4(5):e127. Epub 2006 Apr 25.

40.

Analysis of membrane proteins from human chronic myelogenous leukemia cells: comparison of extraction methods for multidimensional LC-MS/MS.

Ruth MC, Old WM, Emrick MA, Meyer-Arendt K, Aveline-Wolf LD, Pierce KG, Mendoza AM, Sevinsky JR, Hamady M, Knight RD, Resing KA, Ahn NG.

J Proteome Res. 2006 Mar;5(3):709-19.

PMID:
16512687
41.

Obesity alters gut microbial ecology.

Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5. Epub 2005 Jul 20.

42.

AP2-dependent signals from the ectoderm regulate craniofacial development in the zebrafish embryo.

Knight RD, Javidan Y, Zhang T, Nelson S, Schilling TF.

Development. 2005 Jul;132(13):3127-38.

43.

Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway.

Chanalaris A, Lawrence KM, Townsend PA, Davidson S, Jamshidi Y, Stephanou A, Knight RD, Hsu SY, Hsueh AJ, Latchman DS.

Biochem Biophys Res Commun. 2005 Mar 11;328(2):442-8. Erratum in: Biochem Biophys Res Commun. 2005 Apr 29;330(1):356. Jashmidi, Yalda [corrected to Jamshidi, Yalda].

PMID:
15694367
44.

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG.

J Clin Oncol. 2004 Aug 15;22(16):3269-76. Epub 2004 Jul 12.

PMID:
15249589
45.

Improving reproducibility and sensitivity in identifying human proteins by shotgun proteomics.

Resing KA, Meyer-Arendt K, Mendoza AM, Aveline-Wolf LD, Jonscher KR, Pierce KG, Old WM, Cheung HT, Russell S, Wattawa JL, Goehle GR, Knight RD, Ahn NG.

Anal Chem. 2004 Jul 1;76(13):3556-68.

PMID:
15228325
47.
48.

lockjaw encodes a zebrafish tfap2a required for early neural crest development.

Knight RD, Nair S, Nelson SS, Afshar A, Javidan Y, Geisler R, Rauch GJ, Schilling TF.

Development. 2003 Dec;130(23):5755-68. Epub 2003 Oct 8.

49.

Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes.

Chanalaris A, Lawrence KM, Stephanou A, Knight RD, Hsu SY, Hsueh AJ, Latchman DS.

J Mol Cell Cardiol. 2003 Oct;35(10):1295-305.

PMID:
14519439

Supplemental Content

Loading ...
Support Center